Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy

This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy. The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group. More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significantly improved median overall survival to 13.8 months compared to 7.5 months for chemotherapy alone. Future clinical trials will undoubtedly build on the success of current immunotherapies, including VEGF-inhibitors, checkpoint blockades and more. In 2022, researchers will hopefully find ways to improve the effectiveness, response rate and safety of these therapies for mesothelioma patients. The post Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news